Evaluation of TL-925 for the Treatment of Allergic Conjunctivitis

Part of paid clinical trials in Memphis, Tennessee.

Sponsor
Telios Pharma, Inc.
Study ID
NCT06686472
Phase
PHASE2
Status
Recruiting
Apply to this trial

Conditions

  • Allergic Conjunctivitis

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • TL-925 — DRUG
    TL-925 is an eye drop.
  • Placebo — DRUG
    The composition of the placebo is identical to the active formulation except for the exclusion of the active ingredient.

Study Details

In this prospective, Phase 2, randomized, double-masked, vehicle controlled study, approximately 66 eligible subjects will be randomized 1:1 to receive either TL-925 or placebo as topical ophthalmic eye drops administered bilaterally. The study comprises of a screening and treatment period using the conjunctival allergen challenge model to evaluate TL-925 for the treatment of allergic conjunctivitis.

Key Dates

Start date
Oct 3, 2024
Status verified
Nov 2024
Primary completion
Dec 10, 2024
Completion
Dec 10, 2024

Study Design

Enrollment
66 participants (estimated)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Active Comparator: TL-925 Arm
    Subjects will be dosed in clinic.
  • Placebo Comparator: Placebo Arm
    Subjects will be dosed in clinic.

Primary Outcome Measure

Ocular Itching [ Time Frame: 3, 5 and 7 minutes after CAC ]

Central Contacts

Locations (1)

FacilityCityStateZIPSite coordinators
Telios Investigative SiteMemphisTennessee38119-

Find similar trials in Memphis, TN

By research site
Telios Investigative Site· Memphis, TN

Related Studies